DUBLIN, Ohio – December 2024 – Cardinal Health announced the start of weekly production of actinium-225 (Ac-225) through its Center for Theranostics Advancement in Indianapolis, Indiana, in collaboration with TerraPower Isotopes. The routine production will increase the availability of Ac-225 for the manufacturing of investigational therapeutic drug products and provide for the future commercial manufacturing of novel therapies that will help advance patient care.

“Achieving routine production and becoming the first to provide cGMP Ac-225 globally at scale is a significant milestone in Cardinal Health’s work to help increase access to theranostics and potential new cancer therapies for patients,” said Mike Pintek, president, Cardinal Health Nuclear & Precision Health Solutions. “We take pride in our work with TerraPower Isotopes and pharmaceutical innovators on Ac-225 isotope supply for therapeutic product development, investigational clinical study and regulatory approval needs.”

Ac-225 is an alpha-emitting radionuclide that can be attached to small molecules, peptides or antibodies known to target cancerous cells. These drug products are currently being evaluated through worldwide clinical studies as targeted alpha therapies (TATs) for some of the most commonly diagnosed cancers, including prostate, neuroendocrine, breast, colon, melanoma and lymphoma.

Also Read : Philips and Sim&Cure Expand Partnership in Neurovascular Therapy

Cardinal Health’s investments in its Center for Theranostics Advancement have supported the growth of theranostics globally, as the company works with pharmaceutical innovators across their product lifecycles, from concept to commercialization. Growth of the Center for Theranostics Advancement has enabled the company to create strategic collaborations with pharmaceutical manufacturers to support the development and commercialization of new precision medicines as well as the growing demand for cGMP Ac-225.

“We’re committed to making impactful investments as demand for precision medicine continues to increase,” said Pintek. “Our work to supply Ac-225 is a testament to our commitment to support innovative therapeutics to help address the most pressing health issues facing patients today. The use of Ac-225 in clinical trials to treat various cancers shows exciting potential for future patient care. We look forward to assisting with the development of Ac-225 for pharmaceutical manufacturers worldwide.”